

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xuanzhu Biopharmaceutical Co., Ltd.

軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

**VOLUNTARY ANNOUNCEMENT
COMMERCIAL COOPERATION WITH INNOBIC
FOR BIREOCICLIB IN THE THAILAND MARKET**

The board of directors (the “**Board**”) of Xuanzhu Biopharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Group has recently entered into a tri-party commercial agreement (the “**Agreement**”) in respect of Bireociclib Tablets (the “**Target Product**”) with Innobic (Asia) Co., Ltd. (“**Innobic (Asia)**”), a Thai pharmaceutical company, and ZaoAn International Trading Co., Ltd (“**ZaoAn International**”) with a term expiring on 30 June 2036.

Pursuant to the Agreement, the Group jointly grants Innobic (Asia) and ZaoAn International exclusive commercialisation rights for the Target Product within the territory of Thailand (the “**Target Territory**”). The commercialisation rights include the rights to import, promote, market, offer for sale, sell and distribute the Target Product in the Target Territory. Innobic (Asia) will act as the distributor and be responsible for pharmaceutical registration, local marketing and commercial operation of the Target Product in the Target Territory. Under the Agreement, the marketing authorisation for the Target Product will be held in the name of Innobic (Asia). ZaoAn International will act as the intermediary and assume primary payment obligations under purchase orders. The Group will supply the Target Product at the agreed supply prices to support the commercialisation activities of the Target Product in the Target Territory.

The Agreement provides for certain minimum purchase quantities on an annual basis, and licence fees payable by Innobic (Asia) to the Group upon signing and upon obtaining marketing authorisation from the Thai Food and Drug Administration (TFDA). Innobic (Asia) and ZaoAn International are jointly and severally liable to the Group for their respective obligations under the Agreement.

This strategic cooperation is implemented in Thailand, a core member economy of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S). By leveraging international partners to expand overseas markets, the Group will continuously expand the influence of its products across the promising Southeast Asian market, bring economic benefits to the Company and enhance its brand value.

ABOUT BIREOCICLIB

Bireociclib Tablets (trade name: Xuan Yue Ning), as the first CDK2/4/6 inhibitor approved in China, possesses a unique multi-target synergistic mechanism of action, offering advantages including potent inhibition of tumor cell proliferation and significant reduction of the hematological toxicity commonly associated with traditional CDK4/6 inhibitors. In May 2025, Bireociclib Tablets were approved by the National Medical Products Administration (NMPA) for use in combination with fulvestrant for the treatment of adult patients with HR+/HER2- locally advanced or metastatic breast cancer who have experienced disease progression following prior endocrine therapy; and as monotherapy for the treatment of adult patients with HR+/HER2- advanced or metastatic breast cancer who have experienced disease progression following two or more prior endocrine therapies and one chemotherapy regimen during the metastatic stage, making it the first and only CDK2/4/6 inhibitor approved with a monotherapy indication in China. In March 2026, Bireociclib Tablets received approval for an additional indication, for use in combination with aromatase inhibitors (AIs) for the initial endocrine treatment of patients with HR+/HER2- locally advanced or metastatic breast cancer. In December 2025, both indications for Bireociclib Tablets, in combination with fulvestrant and as monotherapy, were included in the National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List (2025), effective from 1 January 2026.

ABOUT INNOBIC (ASIA)

Innobic (Asia) is a life-science company headquartered in Thailand focusing on Southeast Asian businesses and pursuing global commercial opportunities. Innobic (Asia) is a wholly-owned subsidiary of PTT Public Company Limited (“PTT”), a listed company on the Stock Exchange of Thailand and Thailand’s largest state-owned petroleum enterprise. As a national-energy supplier and multinational-enterprise group, PTT has invested in diversified new sectors including life sciences, renewable energy and power value chains. To date, PTT has recorded revenue of over USD80 billion and a market capitalisation exceeding USD33 billion. The strategic objective for PTT to establish Innobic (Asia) is to develop it into a leading ASEAN life-science company focusing on pharmaceuticals, medical-technology and nutrition-related businesses.

ABOUT ZAOAN INTERNATIONAL

ZaoAn International is a trading company established in Hong Kong on 17 September 2021, with experience in cross-border pharmaceutical trade.

IMPLICATIONS UNDER THE LISTING RULES

As the transactions contemplated under the Agreement are revenue-generating transactions in the ordinary and usual course of business of the Group, the entering into of the Agreement does not constitute a notifiable transaction under Chapter 14 of the Listing Rules.

RISK FACTORS

The progress and outcome of regulatory filings and marketing-authorisation approvals for Bireociclib Tablets within the Target Territory under the Agreement are subject to multiple factors, including local regulatory policies and approval requirements, and uncertainties remain as to whether marketing authorisation can be successfully obtained within the Target Territory. In addition, pursuant to the Agreement, Innobic (Asia) is required to pay licence fees and ZaoAn International is required to pay product purchase consideration pursuant to purchase orders. Payments of the aforesaid sums are subject to satisfaction of triggering conditions stipulated under the Agreement. Subsequent actual amounts of licence fees and purchase consideration and relevant payment timelines are contingent upon registration progress and commercial-promotion effectiveness of the product, and realisable revenue therefrom is subject to uncertainties. Investors are advised to exercise caution when making investment decisions and pay attention to investment risks. The Company will strictly comply with applicable laws, regulations and the Listing Rules and duly fulfil its information-disclosure obligations in respect of any material subsequent developments of this project.

This announcement is made by the Company for the purpose of keeping its shareholders and potential investors informed of the Group's latest business developments. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun

Chairperson of the Board and executive Director

Hong Kong, 3 September 2026

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; (iii) Ms. Yue Xin as employee representative Director; and (iv) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.